IL6 and anemia (phenotype): Despite the known association of IL-6 with anemia and CRP levels in RA, only a limited number of small or post hoc studies have evaluated the impact of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (bDMARDs or tsDMARDs) on Hb and CRP levels [15, 20–24].